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Abstract
Age related macular degeneration (AMD) is the most common cause of blindness amongst the elderly. Approximately 10%
of AMD patients suffer from an advanced form of AMD characterized by choroidal neovascularization (CNV). Recent
evidence implicates a significant role for complement in the pathogenesis of AMD. Activation of complement terminates in
the incorporation of the membrane attack complex (MAC) in biological membranes and subsequent cell lysis. Elevated
levels of MAC have been documented on choroidal blood vessels and retinal pigment epithelium (RPE) of AMD patients.
CD59 is a naturally occurring membrane bound inhibitor of MAC formation. Previously we have shown that membrane
bound human CD59 delivered to the RPE cells of mice via an adenovirus vector can protect those cells from human
complement mediated lysis ex vivo. However, application of those observations to choroidal blood vessels are limited
because protection from MAC- mediated lysis was restricted only to the cells originally transduced by the vector. Here we
demonstrate that subretinal delivery of an adenovirus vector expressing a transgene for a soluble non-membrane binding
form of human CD59 can attenuate the formation of laser-induced choroidal neovascularization and murine MAC formation
in mice even when the region of vector delivery is distal to the site of laser induced CNV. Furthermore, this same
recombinant transgene delivered to the intravitreal space of mice by an adeno-associated virus vector (AAV) can also
attenuate laser-induced CNV. To our knowledge, this is the first demonstration of a non-membrane targeting CD59 having
biological potency in any animal model of disease in vivo. We propose that the above approaches warrant further
exploration as potential approaches for alleviating complement mediated damage to ocular tissues in AMD.
Citation: Cashman SM, Ramo K, Kumar-Singh R (2011) A Non Membrane-Targeted Human Soluble CD59 Attenuates Choroidal Neovascularization in a Model of
Age Related Macular Degeneration. PLoS ONE 6(4): e19078. doi:10.1371/journal.pone.0019078
Editor: Alfredo Fusco, Consiglio Nazionale delle Ricerche (CNR), Italy
Received January 6, 2011; Accepted March 24, 2011; Published April 28, 2011
Copyright:  2011 Cashman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by grants to R.K.-S. from The Ellison Foundation, The Virginia B. Smith Trust, NIH/NEI (EY014991 and EY013887) and grants to the
Department of Ophthalmology at Tufts University from the Lions Eye Foundation and Research to Prevent Blindness. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Tufts University has filed patents that include the data in this manuscript. Rajendra Kumar-Singh is a consultant and equity holder in
Hemera Biosciences.
* E-mail: rajendra.kumar-singh@tufts.edu
. These authors contributed equally to this work.
Introduction
Age related macular degeneration (AMD) is the leading cause of
central vision loss and blindness amongst the elderly in the developed
world.Approximately 10% of AMD patientssuffer from the exudative
or wet form of AMD that is characterized by choroidal neovascular-
ization (CNV) and macular edema. The remaining 90% of patients
suffer from the nonexudative or dry form of AMD characterized by
the deposition of drusen or lipoproteinaceous deposits between the
retinal pigment epithelium (RPE) and Bruch’s membrane. A subset of
advanced AMD patients suffer from geographic atrophy (GA),
characterized by a loss of RPE cells and subsequent retinal
degeneration (reviewed in [1]). In general, wet AMD is the major
contributor to vision loss and this form of AMD can be treated
effectively with FDA-approved vascular endothelial growth factor
antibody ranibizumab [2]. However, this current standard of care does
not block the progression of dry AMD. Hence, there is currently no
effective treatment available for 90% of AMD patients.
Recent evidence strongly implicates a role for complement in
the progression of AMD. Specifically, sequence polymorphisms in
complement activators and complement inhibitors have been
associated with AMD (reviewed in [3]). The terminal step of
complement activation involves the incorporation of the mem-
brane attack complex (MAC) in the cell membrane that leads to
their lysis [4,5].
One hypothesis of AMD pathogenesis is that bystander
complement-mediated damage to host tissues essential in main-
taining healthy vision, such as the RPE or choroidal blood vessels
leads to GA or CNV. Support for this hypothesis comes from the
observation of elevated levels of MAC on the RPE as well as
choroidal blood vessels of AMD patients [6,7]. Sub-lytic levels of
MAC are known to signal growth factor release from endothelial
cells [8] and to increase mitogenesis [9], suggestive of a possible
role for MAC in the formation of CNV or the transition of dry to
wet AMD. MAC has been documented to be elevated in the laser
photocoagulation model of wet AMD and attenuation of MAC
inhibits the formation of CNV [10]. Collectively, these data are in
support of the hypothesis that MAC plays a role in AMD.
CD59, also known as protectin or membrane inhibitor of reactive lysis is
a glycosylphosphatidyl inositol (GPI)-anchored membrane inhib-
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functions by binding the C5b678 terminal complement protein
complex and preventing the incorporation of the multiple C9
molecules required to complete the formation of a pore in the cell
membrane [13]. Recombinant soluble forms of CD59 (sCD59)
from which the GPI membrane anchor has been deleted have
been previously described [14,15]. However, relative to mem-
brane-bound CD59, sCD59 has proven to be a poor inhibitor of
MAC both in vitro and in vivo. Studies designed to measure the
MAC-inhibitory capacity of sCD59 have found that in a ‘reactive
lysis’ system where purified components are used to assemble the
MAC on targets, sCD59 can inhibit MAC formation. However, in
the presence of serum, this capacity is significantly diminished
[15,16]. Moreover, in vivo, the small size of sCD59 results in rapid
clearance in the kidney. To our knowledge, there is thus far no
clear reported evidence of a non-membrane binding CD59 being
able to inhibit MAC formation in vivo.
Those early studies on the lack of efficacy of sCD59 in vivo
prompted the development of soluble recombinant membrane-
targeted forms of CD59 that were targeted to membranes via a
membrane address tag [17]. Such novel molecules have
substantially higher levels of activity relative to membrane-free
sCD59 and have been found to be efficacious in a number of
animal models of disease [17,18,19]. Previously, we have shown
that expression of a GPI-anchored human CD59 expressed on
murine RPE in vivo protects those cells from human complement
mediated attack ex vivo [20]. However, only the cells that
synthesized and expressed the CD59 molecule on their surface
were protected from complement-mediated damage. While an
important first step, this approach was limiting and did not lend
itself to application towards inhibition of choroidal neovascular-
ization or targeting of blood vessels- a tissue intimately implicated
in wet AMD. Ideally, a subset of cells ought to be utilized as
‘factories’ for local production and secretion of a soluble CD59 in
order to confer protection to a large number of ocular cells
including the RPE and choroidal blood vessels.
In this study we revisit the use of a non-membrane binding
sCD59 as an inhibitor of MAC formation in vivo using a gene
therapy approach. We believe that the ocular environment in
combination with a gene therapy approach provides unique
opportunities for the use of sCD59 despite previous discouraging
data on the use of this molecule in vivo. We elected to test our
approach of inhibiting MAC in a previously well-described model
of wet AMD i.e, choroidal neovascularization (CNV) induced by
photocoagulation of the Bruch’s membrane. Our results indicate
that sCD59 without the need for any membrane targeting can
significantly attenuate MAC formation and reduce CNV in vivo.
We propose that use of sCD59 delivered by a gene therapy
approach deserves further study as a potential therapy for both the
wet as well as dry forms of AMD.
Results
Soluble human CD59 is correctly processed and secreted
in vitro
A recombinant human adenovirus serotype 5 containing an
expression cassette for human soluble CD59 (sCD59), which lacks
the C-terminal 26 amino acids encoding the signal sequence for
attachment of the GPI anchor, was generated (AdCAGsCD59,
Figure 1A) essentially as described by us previously [20]. An
adenovirus expressing a GFP (AdCAGGFP) and an adenovirus
without a transgene (AdCAGpA) were also used in this study and
have been described previously [20]. AdCAGsCD59 was exam-
ined for efficient expression and secretion of sCD59 by infection of
ARPE-19 cells with either AdCAGsCD59 or a control virus,
AdCAGGFP. After infection, cell lysate and media were harvested
and analyzed by western blot. Media from cells infected with
AdCAGsCD59 confirmed the expression and secretion of sCD59
(Figure 1B), a protein consisting of a number of N-glycosylated
forms of approximately 14–18 kDa. The lysate from these infected
cells exhibited a discrete band at approximately 15 kDa. As
expected, no sCD59 was detected in the lysate or media from
AdCAGGFP-infected ARPE-19 cells.
sCD59 confers protection from human serum-mediated
cell lysis
Murine Hepa-1c1c7 cells were incubated at a final concentra-
tion of 1% normal human serum (NHS) in media pre-conditioned
by media from either AdCAGsCD59 or AdCAGGFP- infected
ARPE-19 cells. As a control, a similar set of studies were
performed using heat inactivated NHS (HI-NHS). One hour post-
incubation, Hepa-1c1c7 cells were analysed for lysis by flow
cytometry for uptake of propidium iodide. A representative
histogram of cell lysis is presented in Figure 2. Whereas lysis of
Hepa-1c1c7 cells treated with NHS and AdCAGGFP-conditioned
media was 79.8762.54% (Figure 2B), lysis of Hepa-1c1c7 cells
treated with NHS and AdCAGsCD59-conditioned media was
52.6664.43%. A small amount of cell lysis was observed in Hepa-
Figure 1. sCD59 is expressed and efficiently secreted from
adenovirus in vitro. (A) Expression cassettes for both sCD59 and GFP
or without a transgene were cloned into the deleted E1 region of an E1/
E3-deleted adenovirus. (B) ARPE-19 cells infected with AdCAGsCD59
express sCD59 and exhibit robust secretion into the media. CAG,
chicken b-actin promoter; pA, polyA; LITR/RITR, left/right inverted
terminal repeat; ¥, packaging signal; DE1/E3, deleted early regions 1/3;
E2/E4, early regions 2/4.
doi:10.1371/journal.pone.0019078.g001
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conditioned media (10.6861.27%) or the AdCAGsCD59-condi-
tioned media (11.0361.92%), which could be the result of cell
manipulation during the experiment (Figure 2B). In conclusion,
AdCAGsCD59-conditioned media conferred a significant
(34.0866.40%, p,0.01) protection against cell lysis mediated by
complement in NHS.
Adenovirus does not influence the size of laser-induced
CNV
Adenovirus has been previously shown to induce complement
activation in vivo [21,22]. To examine whether ocular delivery of
an adenovirus into a mouse would affect the amount of choroidal
neovascularization (CNV) induced by laser burn, we injected a
control virus, AdCAGpA (spiked in a 1:10 ratio with Ad-
CAGGFP to localize the injection site) into the subretinal space of
6 week-old C57Bl6/J mice. 72 hours post-injection, both
AdCAGpA-injected and uninjected mice were subjected to three
laser burns per eye and CNV allowed to develop for 7 days. Eyes
were harvested, cornea, lens, and retina removed, and RPE/
choroid flatmounts stained with a FITC-conjugated lectin specific
for endothelial cells, GSL I, isolectin B4. A representative
micrograph of a CNV spot is presented for both AdCAGpA-
injected and uninjected eyes (Figure 3A). The average size of a
laser CNV spot in AdCAGpA-injected eyecups was
3.7360.78610
4 mm
2, while the average spot size in the
uninjected eyecups was 6.9161.88610
4 mm
2. We therefore
conclude that there was no significant difference in CNV spot
size between AdCAGpA-injected and uninjected eyecups (p.0.5,
Figure 3B), and that adenovirus delivery into the murine
subretinal space does not significantly affect the size of the
CNV induced by a laser burn.
Subretinal delivery of an adenovirus expressing sCD59
leads to a reduction in laser-induced CNV
Each of AdCAGpA and AdCAGsCD59 (spiked in a 1:10 ratio
with AdCAGGFP) were injected into the subretinal space of mice
and eyes treated with laser as described above. 7 days post-laser,
RPE/choroid flatmounts were stained with GSL I. A micrograph
showing the region of adenovirus transduction relative to the sites
of laser burn for each of AdCAGpA and AdCAGsCD59 is shown
(Figure 4A). No significant difference in the area of transduction
(p.0.05) was observed between AdCAGpA-injected eyecups
(1.2860.24610
6 mm
2) relative to AdCAGsCD59-injected eyecups
(1.1960.18610
6 mm
2, Figure 4B). CNV spots from these eyes
were imaged by confocal fluorescent microscopy and the size of
CNV spots measured. A representative micrograph of a CNV spot
from an AdCAGpA-injected and AdCAGsCD59-injected eyecup
is shown (Figure 5A). While the average size of CNV spots from
Figure 2. AdCAGsCD59-conditioned media confers significant
protection from human serum-mediated cell lysis. (A) A
representative FACS histogram for hepa-1c1c7 cells treated with either
NHS or HI-NHS in media conditioned with either AdCAGGFP or
AdCAGsCD59. (B) While no significant difference in cell lysis was
observed in hepa-1c1c7 cells treated with HI-NHS in media conditioned
with either AdCAGGFP or AdCAGsCD59, a significant (34.0866.40%,
**p,0.01) reduction was observed in cell lysis in hepa-1c1c7 cells
treated with NHS in media conditioned with AdCAGsCD59 relative to
those cells treated with NHS in media conditioned with the control
virus, AdCAGGFP. HI-NHS, heat-inactivated normal human serum; NHS,
normal human serum. n=4.
doi:10.1371/journal.pone.0019078.g002
Figure 3. Delivery of adenovirus to mouse subretinal space
does not affect size of laser-induced CNV. Representative
micrographs of FITC-GSL I stained laser-induced CNV spots from each
of AdCAGpA-injected and uninjected eyecups. No significant difference
was observed in the size of spots induced by laser in AdCAGpA-injected
relative to uninjected eyes (p.0.5). n=12 spots/5 eyes (uninjected),
n=26 spots/9 eyes (AdCAGpA); ns, not significant. Scale bar=50 mm.
doi:10.1371/journal.pone.0019078.g003
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4 mm
2, the
average spot size from AdCAGsCD59-injected eyecups was
1.4360.24610
4 mm
2 (Figure 5B). This resulted in a significant
(61.7619.9%, p,0.01) reduction in size of CNV spot by
AdCAGsCD59, indicating that delivery of AdCAGsCD59 to
murine RPE by subretinal injection confers a significant protection
against laser-induced CNV.
Subretinal delivery of an adenovirus expressing sCD59
leads to a reduction in MAC
RPE/choroidal flatmounts injected with either AdCAGpA or
AdCAGsCD59 and subjected to laser burn as described above
were stained with an antibody against mouse C9. MAC staining in
the AdCAGpA-injected eyecups could be observed extending
beyond the region of GSL I staining (5 of 11 spots, Figure 6A),
while in the AdCAGsCD59-injected eyecups MAC deposition was
confined to the region of GSL I staining (20 of 20 spots). This
suggests that cells adjacent to the CNV spot are being protected
from MAC deposition in the AdCAGsCD59-injected eyecups.
Quantification of MAC staining showed a significant 52.5613.4%
(p,0.001) reduction in MAC deposition in AdCAGsCD59-
injected eyecups (Figure 6B) relative to those injected with
AdCAGpA.
Intravitreal delivery of an adeno-associated virus
expressing sCD59 leads to a reduction in laser-induced
CNV
In contrast to subretinal injection, intravitreal injection is a
much more widely used approach for ocular drug delivery and is
used routinely for administration of anti-VEGF treatments for wet
AMD. Adeno-associated virus (AAV) serotype 2 has been shown
to be safe when administered to the vitreous of non-human
primates [23]. The sCD59 or GFP expression cassettes were
cloned into an AAV-2 vector and are referred to as AAV-
CAGsCD59 and AAVCAGGFP respectively (Figure 7A). Expres-
sion of sCD59 was confirmed by western blot analysis of infected
human embryonic retinoblasts (Figure 7B). A unique band at
approximately 15 kDa was observed in the media of cells infected
with AAVCAGsCD59 and as expected, absent from the media of
cells infected with the control virus AAVCAGGFP. AAV-
CAGsCD59 (spiked 1:10 with AAVCAGGFP) was injected into
the vitreous of the eyes of 6–8 week old mice. Control eyes were
similarly injected with AAVCAGGFP alone but both eyes received
the same total number of AAV particles. Between 12 and 19 days
post-injection, the eyes of injected mice were subjected to laser
burn and eyes harvested 7 days post-laser. A representative image
of a laser-induced CNV from each of AAVCAGGFP-injected and
AAVCAGsCD59-injected eyecups is shown (Figure 7C), in which
a significant 62.6616.9% (p,0.001) reduction was observed in
Figure 4. AdCAGpA and AdCAGsCD59 coinjected with Ad-
CAGGFP result in equivalent levels of transduction and at sites
distal to the sites of laser burn. Representative micrographs
showing RPE/choroid flatmounts transduced with AdCAGGFP:Ad-
CAGpA (1:10) and AdCAGGFP:AdCAGsCD59 (1:10). The region of
transduction is demarcated and each of the three laser spots labeled
1–3. No significant difference in area of transduction was observed
between AdCAGpA-injected and AdCAGsCD59-injected eyecups. n=10
eyes (AdCAGsCD59), n=8 eyes (AdCAGpA). ns, not significant. Scale
bar=200 mm.
doi:10.1371/journal.pone.0019078.g004
Figure 5. AdCAGsCD59 delivered to murine RPE results in a
significant reduction in laser-induced CNV. Representative
micrographs showing FITC-GSL I stained laser-induced CNV spots from
eyes injected with either AdCAGpA or AdCAGsCD59. AdCAGsCD59
transduction of murine RPE results in a 61.7619.9% reduction in size of
CNV spot relative to eyes injected with AdCAGpA (**p,0.01). n=33
spots/12 eyes (AdCAGsCD59), n=26 spots/9 eyes (AdCAGpA). Scale
bar=50 mm.
doi:10.1371/journal.pone.0019078.g005
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the control virus, AAVCAGGFP (figure 7D). The average size of
CNV from AAVCAGGFP-injected eyes was 1.3160.23610
5 mm
2,
while that of the AAVCAGsCD59-injected eyecups was
0.4960.08610
5 mm
2. It is noteworthy that CNV lesions in AAV-
injected eyes were larger than in those injected with adenovirus. We
consider that this is possibly due to the increased number of spots (4)
generated in AAV-injected eyes versus adenovirus-injected eyes (3)
as it is likely that the release of growth factors from each lesion may
influence the growth of adjacent lesions.
Figure 6. AdCAGsCD59 results in a significant reduction in MAC deposition at the site of laser-induced CNV. Representative
micrographs showing laser-induced CNV spots from eyes injected with AdCAGpA and AdCAGsCD59 and co-stained with GSL I and anti-C9 antibody
(MAC). For more accurate representation of MAC staining, CNV spots of equivalent size are shown for each of AdCAGpA and AdCAGsCD59. The
overlay illustrates deposition of MAC extending beyond the region staining positive for GSL I, particularly in the AdCAGpA-injected eyecup. A
significant (52.5613.4%, ***p,0.001) reduction in MAC deposition was observed in regions of laser burn in AdCAGsCD59-injected eyecups relative to
those injected with AdCAGpA. n=11 spots/4eyes (AdCAGpA), n=20 spots/7 eyes (AdCAGsCD59). Scale bar=50 mm.
doi:10.1371/journal.pone.0019078.g006
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Substantial genetic, biochemical as well as histological evidence
now exists that links complement activation with the pathogenesis
of AMD. Based on this cumulative evidence, a number of clinical
trials examining the safety and efficacy of various inhibitors of
complement are now under way. These trials are targeting either
complement component C3 via a small peptide (compstatin/POT-
4), complement component C5 via an antibody (eculizumab) or
aptamer (ARC1905), or Factor D via an antibody (TNX-234)
(reviewed in [24]). The complement system plays an essential role
in innate immunity against microbes and orchestrates immuno-
logical and inflammatory processes. Naturally occurring deficien-
cies of specific complement components highlight the need for a
fully functional complement system. For example, C3 or C5
deficiency has previously been associated specifically with
Neisseria and meningococcal meningitis infections respectively
[25,26,27]. Hence, blocking the activity of C3 or C5 may
potentially expose individuals to bacterial infections. Furthermore,
a block in C3 or C5 activation would also result in a block in
production of anaphylatoxins C3a and C5a that act directly on
neutrophils and monocytes to speed up the phagocytosis of
pathogens or function in the activation of mast cells and antibody
recruitment. Complement is also involved in diverse processes
such as synapse formation, angiogenesis, mobilization of hemato-
poietic stem-progenitor cells, tissue regeneration and lipid
metabolism (reviewed in [28]). Accordingly, it has recently been
suggested that loss of synapses via complement may play a role in
glaucoma [29]. These diverse functions of complement further
highlight the need for an intact complement system. In view of
these considerations, it may be advantageous to leave as much of
the complement system intact as possible and attenuate only the
Figure 7. Intravitreal delivery of an AAV expressing sCD59 results in a significant protection against laser-induced CNV. (A) The
expression cassette containing sCD59 under the control of the chicken b-actin promoter was cloned into an AAV serotype 2 vector. A control virus
expressing GFP was also generated. (B) Western blot analysis confirms secretion of sCD59 by human embryonic retinoblasts infected with
AAVCAGsCD59. (C) Representative micrographs of laser-induced CNV spots observed in AAVCAGGFP-injected and AAVCAGsCD59-injected eyecups.
(D) A significant 62.6616.9% (***p,0.001) reduction in size of CNV was observed in AAVCAGsCD59-injected eyecups relative to those injected with
AAVCAGGFP. n=42 spots/11 eyes (AAVCAGGFP), n=53 spots/14 eyes (AAVCAGsCD59). Scale bar=50 mm.
doi:10.1371/journal.pone.0019078.g007
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of MAC. Blocking the formation of MAC via CD59 satisfies these
criteria, notwithstanding the possibility that pathogens may be
capable of recruiting sCD59 to their surfaces and evading
complement mediated lysis.
Peptides and antibodies have limited half-lives in vivo and need
to be readministered on a regular basis. For example, wet AMD
patients receive intraocular ranibizumab antibody injections every 4
to 6 weeks. This exposes patients to complications associated with
endophthalmitis. Whereas the incidence of endophthalmitis is
relatively low (0.16% per dose) in the presence of a robust immune
system [30], this rate is likely to substantially increase due to the
cumulative effect of an attenuated complement system and serial
injections over many years for chronic diseases such as AMD.
Hence, frequent injection of complement inhibitors into AMD
eyes may not be desirable. Limiting the frequency of administra-
tion may be satisfied via a gene therapy approach as we have done
in this study.
Viral vectors such as adenovirus have previously enabled
transgene expression in vivo in mice for their lifetime [31]. AAV
vectors have enabled transgene expression in dogs for more than 7
years (reviewed in [32]). In humans, AAV has been found to have
therapeutic transgene expression for over 3.7 years [33]- the longest
time periods studied. We selected adenovirus as a gene delivery
vector because we have previously found it to be an efficient vector
for delivery of transgenes to ocular tissues [20,34,35] as well as the
observation that adenovirus has been found to be safe in several
ocular gene therapy trials [36,37,38]. Adenovirus vectors can be
designed to permit long-term transgene expression and the
technology for scaled production of such vectors is well described
[31]. Nonetheless, we demonstrated that our observations may be
extended to AAV vectors as well. Such vectors have previously been
shown to be safe for use in humans and are generally considered less
immunogenic than adenovirus vectors. While not directly examined
in this study, it is likely that sCD59 delivered to AMD eyes via an
AAV vector would permit long-term transgene expression.
Moreover, given that sCD59 is already found naturally [39] in
ocular tissues (albeit not likely at the levels following recombinant
transgene expression) the prospect of an immune response against
sCD59 is further diminished.
Previously, we have shown that GPI-anchored human CD59
delivered via an adenovirus vector in vivo can protect murine RPE
from human serum-mediated lysis ex vivo [20]. However, as
anticipated, protection was conferred only upon the cells that were
transduced by the vector. In human AMD eyes, MAC is found not
only on the RPE but also on the choroidal blood vessels and
Bruch’s membrane. Since delivery of the vector to all of these cells
and membranes via an intraocular approach is not technically
feasible, we embarked upon testing the efficacy of a soluble non-
membrane associated version of CD59 (sCD59). Prior studies have
found that sCD59 is not efficacious in vivo and hence a variety of
approaches employing recombinant sCD59 with membrane
targeting addresses or sCD59 fusion proteins have been described
[17]. The structure of the ocular compartments provides unique
barriers when targeting cells in the outer ocular tissues (RPE,
choroid) via subretinal or intravitreal delivery. Any membrane-
targeting molecule injected into the subretinal space is not likely to
reach the choroidal blood vessels due to sequestration by the RPE
membrane. Similarly, any membrane-targeting molecule injected
into the vitreous is likely to be sequestered by the cells lining the
vitreous cavity. Hence, a diffusible soluble CD59 might be
necessary to overcome the above barriers.
One complication and apparent limitation of our studies is due
to the small size of the mouse eye that sometimes leads to traction
and partial detachment of the retina during intravitreal injection.
Such detachments are self-resolving within 24 hours. Delivery of
AAV expressing GFP into the vitreous of mice sometimes led to
transduction of the RPE, presumably through retinal detachment
during the injection procedure. These observations highlight the
limitations of the small mouse eye and studies in larger eyes, for
example dogs, pigs or non-human primates are warranted to
extend the observations associated with intravitreal delivery of
AAV for delivery of transgene products to the outer retina. Recent
studies performed in non-human primates receiving an intravitreal
injection of an AAV vector expressing modified soluble VEGF
receptor (sFLT01) have observed a reduction in laser induced
CNV [40]. Given that sCD59 has a significantly lower molecular
weight than sFLT01, it is likely that it too can permeate the non-
human primate retina, but this remains to be demonstrated.
Previous studies in mice in which membrane-targeting murine or
rat CD59 have been injected into the vitreous did not include an
approach to detect retinal detachment occurring during the
intravitreal injection and hence unintended access to the subretinal
space may have occurred [10,19].
In summary, we have shown for the first time that membrane
targeting of sCD59 is not required to inhibit MAC formation in
vivo. We have demonstrated that human sCD59 delivered via a
gene therapy approach can attenuate CNV in mice using either
an adenovirus vector injected subretinally or an AAV vector
injected intravitreally. We have also demonstrated that sCD59
can reduce the extent of MAC deposition on laser-induced CNV
spots. Our results suggest that further studies are warranted
towards the development of sCD59 as a therapy for the wet as
well as dry forms of AMD and possibly other ocular diseases of
complement.
Methods
Generation of adenovirus and AAV constructs
Human CD59 lacking the sequence encoding the C-terminal 26
amino acids was amplified by PCR using the primers CD59XH2F
(59-CCCCCTCGAGTGGACAATCAC AATGGG-39) and CD-
59StopEV-R (59-TAAGGAGATATCTTAATTTTCAAGCTG-
TT CGTTA-39) from the cDNA obtained from American Type
Culture Collection. The reverse primer introduces a stop codon
after asparagine 77. The PCR product was digested with XhoI
(New England Biolabs) and EcoRV (New England Biolabs) and
ligated with a similarly-digested pShCAG [20] pShCAG was
recombined with pAdEasy-1 and used to generate the adenovirus,
AdCAGsCD59, as previously described [20]. The control viruses,
AdCAGGFP and AdCAGpA have been described previously [20].
AAVCAGsCD59 was generated by insertion of the CAGsCD59pA
expression cassette (as employed in the adenovirus construct) into
pAAV-MCS (Stratagene) to generate pAAVCAGsCD59 (further
cloning details available upon request). The AAVCAGsCD59 virus
was produced and purified by the UMass Vector Core Facility,
using AAV serotype 2 capsid proteins. An AAV-2 vector expressing
GFP from a chicken b-actin promoter (AAVCAGGFP) was
purchased from the vector core facility.
Western analysis
Adenovirus: ARPE-19 cells (ATCC) were infected with either
AdCAGsCD59 or AdCAGGFP at an MOI 1000 in DMEM
(Invitrogen). Cell lysate and media were loaded on a 10% Tris-
HCl gel (Bio-Rad Criterion). The membrane was probed with an
anti-CD59 antibody ((N-20) sc-7077, Santa Cruz), followed by a
HRP-bovine anti-goat antibody (Jackson ImmunoResearch).
AAV: Human embryonic retinoblasts [41] were infected at an
Gene Therapy for Age Related Macular Degeneration
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media was analyzed as for adenovirus.
NHS-mediated cell lysis
ARPE-19 cells were infected with either AdCAGsCD59 or
AdCAGGFP at an MOI 1000 in serum-free DMEM without
phenol red and maintained at 37uC/5%CO2. Three days post-
infection, media was collected and centrifuged at 2500RPM to
remove any cells. Hepa-1c1c7 cells were resuspended in media
conditioned by infected ARPE-19 cells and either normal human
serum (NHS) or heat-inactivated NHS (final concentration of 1%)
and incubated at 37uC with constant gentle rotatory motion. One
hour post-incubation, propidium iodide was added to cells (2 mg/
ml) and uptake analyzed by flow cytometry. 2.5610
4 cells were
counted per sample (FACSCalibur, Becton Dickinson) and
analyzed (CellQuest Pro software, Becton Dickinson).
Intraocular injections
The use of animals in this work was in accordance with the
Statement for the Use of Animals in Ophthalmic and Vision
Research, set out by the Association for Research in Vision and
Ophthalmology. This study was approved by Tufts University
Institutional Animal Care and Use Committee (IACUC) protocol
B2009-03 and Tufts University Institutional Biosafety Committee
registration 2008-BRIA27. C57BL/6J mice were purchased from
Jackson Laboratories (Bar Harbor, ME), bred and maintained in a
12-hour light–dark cycle and cared for in accordance with federal,
state and local regulations. Mice were anesthetized by intraper-
itoneal injection of 0.1 ml/10 g of xylazine (10 mg/ml)/ketamine
(1 mg/ml). Subretinal or intravitreal injections were performed
with a 32 G needle attached to a 5 ml glass syringe (Hamilton,
Reno, NV) by a trans-scleral trans-choroidal approach to deliver
2.4610
7 total particles of adenovirus or 8610
9 genome copies of
AAV. Both eyes of each mouse were injected with the same virus.
Laser Induced Choroidal Neovascularization
Mice were anesthetized as described above, and pupils dilated
with a drop each of 2.5% phenylephrine HCl/1% Tropicamide
(Bausch and Lomb). A drop of Hypromellose/Gonak (2.5%,
Akorn, Inc) was applied to the cornea and the back of the eye
viewed with the aid of a microscope and cover slip held on the
cornea. An argon laser (532 nm) set at 100 milliseconds and
150 mW was used to generate three laser spots (75 mm) in each
eye (adenovirus) or four laser spots per eye (AAV).
Staining and imaging of RPE/choroid flatmounts
Mice were sacrificed by CO2 inhalation and eyes harvested 7
days post-laser treatment. Optic nerve, cornea, lens, iris and retina
were removed and the RPE/choroid/sclera (referred to as RPE/
choroid) fixed overnight in 4% paraformaldehyde. RPE/choroid
tissue was incubated in 2.5 mg/ml BSA in PBS for 30 mins at
37uC, followed by 100 mg/ml FITC-conjugated Griffonia Sim-
plicifolia Lectin I (GSL I, isolectin B4, Vector Labs) in PBS for
1 hour at 37uC. For MAC staining, RPE/choroid was incubated
with 6% normal goat serum in 0.3% Triton-PBS (PBST) for
30 mins at RT, followed by a 1:200 dilution of rabbit anti-mouse
C9 antibody (kind gift of B. Paul Morgan) in PBST for 2.5 hours
at RT and a 1:400 dilution of CY3-conjugated goat anti-rabbit
(Jackson ImmunoResearch) at RT for 1 hour. Flatmounts were
imaged using both conventional microscopy using an Olympus
IX51 with appropriate filters, a Retiga 2000R FAST camera and
QCapture Pro 5.0 (QImaging, British Columbia, Canada)
software and by confocal microscopy using a Leica TPS SP2.
Measurement of laser spots, adenoviral transduction, and
intensity of MAC staining
Area of both GSL I-stained spots and adenoviral transduction
was measured using ImageJ software (developed by Wayne
Rasband, National Institutes of Health, Bethesda, MD; available
at http://rsb.info.nih.gov/ij/index.html). Intensity of MAC stain-
ing was determined by measurement of pixel intensity within the
area of the laser spot using ImageJ. Background pixel intensity of
each image was subtracted from pixel intensity of the spot. Area
and intensity measurements were analyzed with Prism 5
(GraphPad Software, Inc) using an unpaired student’s t-test. All
data is presented as Mean6SEM.
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